DE602006021776D1 - Als kinaseinhibitoren geeignete aminopyrimidine - Google Patents

Als kinaseinhibitoren geeignete aminopyrimidine

Info

Publication number
DE602006021776D1
DE602006021776D1 DE602006021776T DE602006021776T DE602006021776D1 DE 602006021776 D1 DE602006021776 D1 DE 602006021776D1 DE 602006021776 T DE602006021776 T DE 602006021776T DE 602006021776 T DE602006021776 T DE 602006021776T DE 602006021776 D1 DE602006021776 D1 DE 602006021776D1
Authority
DE
Germany
Prior art keywords
compounds
kinaseinhibitors
aminopyrimidines
compositions
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021776T
Other languages
English (en)
Inventor
Damien Fraysse
Andrew Miller
Daniel Robinson
Joanne Pinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE602006021776D1 publication Critical patent/DE602006021776D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602006021776T 2005-11-16 2006-11-16 Als kinaseinhibitoren geeignete aminopyrimidine Active DE602006021776D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73706405P 2005-11-16 2005-11-16
PCT/US2006/044636 WO2007059299A1 (en) 2005-11-16 2006-11-16 Aminopyrimidines useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
DE602006021776D1 true DE602006021776D1 (de) 2011-06-16

Family

ID=37806123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021776T Active DE602006021776D1 (de) 2005-11-16 2006-11-16 Als kinaseinhibitoren geeignete aminopyrimidine

Country Status (9)

Country Link
US (1) US20070179125A1 (de)
EP (1) EP1951716B1 (de)
JP (1) JP2009515992A (de)
CN (1) CN101360740A (de)
AT (1) ATE508126T1 (de)
AU (1) AU2006315334B2 (de)
CA (1) CA2629781A1 (de)
DE (1) DE602006021776D1 (de)
WO (1) WO2007059299A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128709T2 (de) 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
JP2009511628A (ja) * 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
NZ594385A (en) 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP5331681B2 (ja) * 2006-04-20 2013-10-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
AU2007317435A1 (en) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
DE602007007985D1 (de) * 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
CN101668760B (zh) * 2007-03-09 2013-07-24 沃泰克斯药物股份有限公司 用作蛋白激酶抑制剂的氨基嘧啶类
AU2008226461A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
WO2008112642A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008128009A2 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011810A (es) 2007-05-02 2010-01-14 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
JP5389786B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
EP2166849A4 (de) * 2007-06-11 2010-09-15 Miikana Therapeutics Inc Substituierte pyrazol-verbindungen
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2010538003A (ja) * 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
WO2009042435A1 (en) 2007-09-21 2009-04-02 Array Biopharma Inc. Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2009073224A1 (en) * 2007-12-07 2009-06-11 Ambit Biosciences Corp. Methods of treating certain diseases using pyrimidine derivatives
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010009985A2 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135908A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EP2408769A1 (de) 2009-03-17 2012-01-25 Glaxo Group Limited Als itk-inhibitoren verwendete pyrimidinderivate
AU2010229140A1 (en) 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
KR20140062079A (ko) 2011-08-25 2014-05-22 에프. 호프만-라 로슈 아게 세린/트레오닌 pak1 억제제
JP2015504876A (ja) 2011-12-22 2015-02-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体
EP2852586A1 (de) 2012-03-16 2015-04-01 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazol-kinaseinhibitoren
CN106977495B (zh) 2012-04-24 2020-08-04 沃泰克斯药物股份有限公司 Dna-pk抑制剂
US9340536B2 (en) * 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
ES2900061T3 (es) 2013-03-12 2022-03-15 Vertex Pharma Inhibidores de DNA-PK
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3424920B1 (de) 2013-10-17 2020-04-15 Vertex Pharmaceuticals Incorporated Co-kristalle von (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)chinolin-4-carboxamid und deuterierte derivate davon als dna-pk-hemmer
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
KR101726648B1 (ko) * 2016-02-29 2017-04-14 한국화학연구원 신규한 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 drak 관련 질환의 예방 또는 치료용 약학적 조성물
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
ES2862374T3 (es) 2016-12-28 2021-10-07 Minoryx Therapeutics S L Compuestos de isoquinolina, métodos para su preparación y usos terapéuticos de los mismos en afecciones asociadas con la alteración de la actividad de beta galactosidasa
CN106841420A (zh) * 2016-12-30 2017-06-13 广州中大南沙科技创新产业园有限公司 一种LC‑MS/MS测定大鼠血浆中Ly‑7u浓度的方法
DK3672965T3 (da) 2017-10-27 2022-10-03 Theravance Biopharma R&D Ip Llc Pyramidinforbindelse som Jak-kinase-inhibitor
JP2022502496A (ja) * 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
BR112023003517A2 (pt) * 2020-08-26 2023-05-09 Nalo Therapeutics Moduladores da proteína proto-oncogênica da família myc
WO2023164612A1 (en) * 2022-02-25 2023-08-31 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1242385B1 (de) * 1999-12-28 2009-11-25 Pharmacopeia, Inc. Cytokine, insbesondere tnf-alpha, hemmer
KR100947185B1 (ko) * 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
EP1397142A4 (de) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co Pyrimidin-hemmer der phosphodiesterase (pde) 7
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2004283137A1 (en) * 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
NZ594385A (en) * 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors

Also Published As

Publication number Publication date
US20070179125A1 (en) 2007-08-02
ATE508126T1 (de) 2011-05-15
EP1951716B1 (de) 2011-05-04
AU2006315334B2 (en) 2011-05-19
CA2629781A1 (en) 2007-05-24
AU2006315334A1 (en) 2007-05-24
WO2007059299A1 (en) 2007-05-24
JP2009515992A (ja) 2009-04-16
EP1951716A1 (de) 2008-08-06
CN101360740A (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
TW200736250A (en) Aminopyrimidines useful as kinase inhibitors
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
ATE542814T1 (de) Pyrazinkinaseinhibitoren
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
TW200633980A (en) Pyridones useful as inhibitors of kinases
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen